{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:46:52Z","timestamp":1778294812956,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Sci & Tech Program","award":["CJ20220064, CJ20243007"],"award-info":[{"award-number":["CJ20220064, CJ20243007"]}]},{"name":"Changzhou Sci & Tech Program","award":["CJ20220064, CJ20243007"],"award-info":[{"award-number":["CJ20220064, CJ20243007"]}]},{"name":"Youth Talent Science and Technology Project of Changzhou Health Commission","award":["QN202434"],"award-info":[{"award-number":["QN202434"]}]},{"name":"Top Talent of Changzhou The 14th Five-Year Plan High-level Health Personnel Training Project","award":["2022260"],"award-info":[{"award-number":["2022260"]}]},{"name":"2023 Changzhou Health Commission Science and Technology Project","award":["QY202301"],"award-info":[{"award-number":["QY202301"]}]},{"name":"Science and Technology Project of Changzhou Health Commission","award":["ZD202428"],"award-info":[{"award-number":["ZD202428"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01778-w","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:12:42Z","timestamp":1754464362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role and mechanism of ARID1A in immunotherapy of gastric cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Wenting","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dachuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"3","key":"1778_CR1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1778_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1778_CR3","first-page":"CD004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1778_CR4","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179\u2013203.","journal-title":"Cancer Metastasis Rev"},{"issue":"16","key":"1778_CR5","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.3390\/jcm10163612","volume":"10","author":"S Oh","year":"2021","unstructured":"Oh S, Kim E, Lee H. Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastric\/gastroesophageal junction cancer treatment: a systematic review and meta-analysis. J Clin Med. 2021;10(16):3612.","journal-title":"J Clin Med"},{"issue":"7","key":"1778_CR6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"key":"1778_CR7","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Pei Y, Luo J, et al. Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice. Front Immunol. 2020;11:1088.","journal-title":"Front Immunol"},{"key":"1778_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661\u201374.","journal-title":"Comput Struct Biotechnol J"},{"issue":"22","key":"1778_CR9","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.2217\/fon-2021-0176","volume":"17","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, et al. KEYNOTE-859: a phase III study of pembrolizumab plus chemotherapy in gastric\/gastroesophageal junction adenocarcinoma. Future Oncol. 2021;17(22):2847\u201355.","journal-title":"Future Oncol"},{"issue":"10","key":"1778_CR10","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang Y-J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"10294","key":"1778_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, England). 2021;398(10294):27\u201340.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"1778_CR12","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/jcm12072636","volume":"12","author":"Y Narita","year":"2023","unstructured":"Narita Y, Muro K. Updated immunotherapy for gastric cancer. J Clin Med. 2023;12(7):2636.","journal-title":"J Clin Med"},{"issue":"20","key":"1778_CR13","doi-asserted-by":"crossref","first-page":"15321","DOI":"10.3390\/ijms242015321","volume":"24","author":"W Hou","year":"2023","unstructured":"Hou W, Zhao Y, Zhu H. Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects. Int J Mol Sci. 2023;24(20):15321.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1778_CR14","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1128\/MCB.20.9.3137-3146.2000","volume":"20","author":"PB Dallas","year":"2000","unstructured":"Dallas PB, Pacchione S, Wilsker D, et al. The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol. 2000;20(9):3137\u201346.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1778_CR15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00418-020-01892-8","volume":"154","author":"S Fantone","year":"2020","unstructured":"Fantone S, Mazzucchelli R, Giannubilo SR, et al. AT-rich interactive domain 1A protein expression in normal and pathological pregnancies complicated by preeclampsia. Histochem Cell Biol. 2020;154(3):339\u201346.","journal-title":"Histochem Cell Biol"},{"issue":"3","key":"1778_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","volume":"26","author":"KC Helming","year":"2014","unstructured":"Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI\/SNF complexes in cancer. Cancer Cell. 2014;26(3):309\u201317.","journal-title":"Cancer Cell"},{"key":"1778_CR17","doi-asserted-by":"crossref","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","volume":"100","author":"J Mullen","year":"2021","unstructured":"Mullen J, Kato S, Sicklick JK, et al. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1778_CR18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7150\/jca.41296","volume":"11","author":"T Jiang","year":"2020","unstructured":"Jiang T, Chen X, Su C, et al. Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes. J Cancer. 2020;11(4):776\u201380.","journal-title":"J Cancer"},{"issue":"12","key":"1778_CR19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ng.982","volume":"43","author":"K Wang","year":"2011","unstructured":"Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219\u201323.","journal-title":"Nat Genet"},{"issue":"3","key":"1778_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5230\/jgc.2015.15.3.201","volume":"15","author":"K-J Kim","year":"2015","unstructured":"Kim K-J, Jung HY, Oh M-H, et al. Loss of ARID1A expression in gastric cancer: correlation with mismatch repair deficiency and clinicopathologic features. J Gastric Cancer. 2015;15(3):201\u20138.","journal-title":"J Gastric Cancer"},{"issue":"1","key":"1778_CR21","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41598-019-43293-5","volume":"9","author":"M Ashizawa","year":"2019","unstructured":"Ashizawa M, Saito M, Min AKT, et al. Prognostic role of ARID1A negative expression in gastric cancer. Sci Rep. 2019;9(1):6769.","journal-title":"Sci Rep"},{"key":"1778_CR22","doi-asserted-by":"crossref","first-page":"787897","DOI":"10.3389\/fonc.2022.787897","volume":"12","author":"L Nan","year":"2022","unstructured":"Nan L, Wang C, Wang J, et al. ARID1A downregulation predicts high PD-L1 expression and worse clinical outcome in patients with gallbladder cancer. Front Oncol. 2022;12:787897.","journal-title":"Front Oncol"},{"issue":"21","key":"1778_CR23","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1158\/0008-5472.CAN-19-1302","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto T, Fatkhutdinov N, Zundell JA, et al. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. 2019;79(21):5482\u20139.","journal-title":"Cancer Res"},{"issue":"3","key":"1778_CR24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3748\/wjg.v17.i3.290","volume":"17","author":"S Nobili","year":"2011","unstructured":"Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric c ancer. World J Gastroenterol. 2011;17(3):290\u20139.","journal-title":"World J Gastroenterol"},{"issue":"21","key":"1778_CR25","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","volume":"40","author":"M Wanior","year":"2021","unstructured":"Wanior M, Kramer A, Knapp S, et al. Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy. Oncogene. 2021;40(21):3637\u201354.","journal-title":"Oncogene"},{"issue":"6001","key":"1778_CR26","first-page":"228","volume":"330","author":"S Jones","year":"2010","unstructured":"Jones S, Wang T-L, Shih I-M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Sci Cult. 2010;330(6001):228\u201331.","journal-title":"Sci Cult"},{"issue":"16","key":"1778_CR27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"1778_CR28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592\u2013601.","journal-title":"Nat Genet"},{"key":"1778_CR29","doi-asserted-by":"crossref","first-page":"28919","DOI":"10.1038\/srep28919","volume":"6","author":"L Yang","year":"2016","unstructured":"Yang L, Wei S, Zhao R, et al. Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies. Sci Rep. 2016;6:28919.","journal-title":"Sci Rep"},{"issue":"5","key":"1778_CR30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5009\/gnl220342","volume":"17","author":"JY Kim","year":"2023","unstructured":"Kim JY, Park CK, Noh S, et al. Prognostic significance of ARID1A expression patterns varies with molecular subtype in advanced gastric cancer. Gut Liver. 2023;17(5):753\u201365.","journal-title":"Gut Liver"},{"issue":"8","key":"1778_CR31","doi-asserted-by":"crossref","first-page":"e0182692","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"Gu L, Chen M, Guo D, et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS ONE. 2017;12(8):e0182692.","journal-title":"PLoS ONE"},{"key":"1778_CR32","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","volume":"10","author":"Y Wu","year":"2019","unstructured":"Wu Y, Chen W, Xu ZP, et al. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022.","journal-title":"Front Immunol"},{"key":"1778_CR33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2022.10.012","volume":"178","author":"SPL Saw","year":"2023","unstructured":"Saw SPL, Ng WP, Zhou S, et al. PD-L1 score as a prognostic biomarker in Asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2023;178:139\u201349.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1778_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang Y-J, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1778_CR35","first-page":"188615","volume":"1876","author":"K Li","year":"2021","unstructured":"Li K, Zhang A, Li X, et al. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta. 2021;1876(2):188615.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"1778_CR36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/cells8070678","volume":"8","author":"L Li","year":"2019","unstructured":"Li L, Li M, Jiang Z, et al. ARID1A mutations are associated with increased immune activity in gastrointestinal cancer. Cells. 2019;8(7):678.","journal-title":"Cells"},{"issue":"5","key":"1778_CR37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"1778_CR38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10020-020-00208-9","volume":"26","author":"D Sun","year":"2020","unstructured":"Sun D, Tian L, Zhu Y, et al. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer. Mol Med. 2020;26(1):78.","journal-title":"Mol Med"},{"issue":"17","key":"1778_CR39","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.21037\/atm-20-922","volume":"8","author":"Y He","year":"2020","unstructured":"He Y, Wang X. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. Ann Transl Med. 2020;8(17):1050.","journal-title":"Ann Transl Med"},{"key":"1778_CR40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","volume":"59","author":"Q Yang","year":"2019","unstructured":"Yang Q, Jiang W, Hou P. Emerging role of PI3K\/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112\u201324.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"1778_CR41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","volume":"46","author":"M Martini","year":"2014","unstructured":"Martini M, De Santis MC, Braccini L, et al. PI3K\/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372\u201383.","journal-title":"Ann Med"},{"issue":"11","key":"1778_CR42","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/modpathol.2013.96","volume":"26","author":"T Bosse","year":"2013","unstructured":"Bosse T, ter Haar NT, Seeber LM, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013;26(11):1525\u201335.","journal-title":"Mod Pathol"},{"issue":"7","key":"1778_CR43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/modpathol.2013.216","volume":"27","author":"H-N Huang","year":"2014","unstructured":"Huang H-N, Lin M-C, Huang W-C, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol. 2014;27(7):983\u201390.","journal-title":"Mod Pathol"},{"key":"1778_CR44","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.2147\/CMAR.S207329","volume":"11","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wang X, Yang J, et al. Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC. Cancer Manag Res. 2019;11:4931\u201346.","journal-title":"Cancer Manag Res"},{"issue":"29","key":"1778_CR45","doi-asserted-by":"crossref","first-page":"46127","DOI":"10.18632\/oncotarget.10060","volume":"7","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Yan H-B, Wang J, et al. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget. 2016;7(29):46127\u201341.","journal-title":"Oncotarget"},{"issue":"2","key":"1778_CR46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/j.gastro.2022.04.020","volume":"163","author":"Y Fukunaga","year":"2022","unstructured":"Fukunaga Y, Fukuda A, Omatsu M, et al. Loss of ARID1A and Pten in pancreatic ductal cells induces intraductal tubulopapillary neoplasm via the YAP\/TAZ pathway. Gastroenterology. 2022;163(2):466-480.e466.","journal-title":"Gastroenterology"},{"key":"1778_CR47","doi-asserted-by":"crossref","first-page":"e12750","DOI":"10.7717\/peerj.12750","volume":"10","author":"S Tessiri","year":"2022","unstructured":"Tessiri S, Techasen A, Kongpetch S, et al. Therapeutic targeting of ARID1A and PI3K\/AKT pathway alterations in cholangiocarcinoma. PeerJ. 2022;10:e12750.","journal-title":"PeerJ"},{"issue":"4","key":"1778_CR48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cellsig.2008.11.015","volume":"21","author":"YR Chin","year":"2009","unstructured":"Chin YR, Toker A. Function of Akt\/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 2009;21(4):470\u20136.","journal-title":"Cell Signal"},{"issue":"14","key":"1778_CR49","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.18632\/oncotarget.2092","volume":"5","author":"EP Samartzis","year":"2014","unstructured":"Samartzis EP, Gutsche K, Dedes KJ, et al. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget. 2014;5(14):5295\u2013303.","journal-title":"Oncotarget"},{"issue":"16","key":"1778_CR50","doi-asserted-by":"crossref","first-page":"e155899","DOI":"10.1172\/jci.insight.155899","volume":"7","author":"H Rehman","year":"2022","unstructured":"Rehman H, Chandrashekar DS, Balabhadrapatruni C, et al. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight. 2022;7(16):e155899.","journal-title":"JCI Insight"},{"issue":"1","key":"1778_CR51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3892\/or.2015.4397","volume":"40","author":"L Yang","year":"2018","unstructured":"Yang L, Yang G, Ding Y, et al. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. Oncol Rep. 2018;40(1):479\u201387.","journal-title":"Oncol Rep"},{"key":"1778_CR52","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.2147\/OTT.S139664","volume":"10","author":"D Lee","year":"2017","unstructured":"Lee D, Yu EJ, Ham I-H, et al. AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells. Onco Targets Ther. 2017;10:4153\u20139.","journal-title":"Onco Targets Ther"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01778-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:52Z","timestamp":1764917572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01778-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01778-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of our hospital and was conducted in accordance with the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"277"}}